首页> 外文OA文献 >Overview of anti‐BCMA CAR‐T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma

【2h】

Overview of anti‐BCMA CAR‐T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma

机译：多发性骨髓瘤的抗BCMA CAR-T免疫疗法概述，复发/难治多骨髓瘤

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Deming Feng; Jian Sun;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE) [J] . Mailankody Sham, Htut Myo, Lee Kelvin P., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：JCARH125，抗BCMA汽车T细胞治疗复发/难治性多发性骨髓瘤：初始证明概念来自阶段1/2多中心研究（Evolve）
2. Successful Treatment of Relapsed/Refractory Extramedullary Multiple Myeloma With Anti-BCMA CAR-T Cell Therapy Followed by Haploidentical Hematopoietic Stem Cell Transplantation: A Case Report and a Review of the Contemporary Literature [J] . Ying Qian, Zijun Qian, Xiujie Zhao, Frontiers in Medicine . 2021,第a期

机译：用抗BCMA Car-T细胞疗法的复发/难治性髓外骨髓瘤的成功治疗随后是Haploidentical造血干细胞移植：案例报告和对当代文学的审查
3. A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma [J] . Robert F Cornell, Jinghui Dong, John B Le Gall, American Journal of Cancer Research . 2021,第6期

机译：一期，多中心研究评估KITE-585的安全性和功效，复发/难治性多发性骨髓瘤患者的自体抗BCMA汽车T细胞疗法
4. Durability of Response with Thalidomide Therapy for Relapsed Multiple Myeloma [C] . B. Myers, S.G. Jones, G. Do I an European Haematology Association . 2002

机译：耐久性耐久性与多发性骨髓瘤复发疗法
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease [O] . Haobin Deng, Meijing Liu, Ting Yuan, 2021

机译：人源化抗BCMA汽车T细胞治疗在复发/难治性多发性骨髓瘤患者中的疗效无需髓情况疾病
7. A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia [O] . Chunrui Li, Wenyue Cao, Yimei Que, 2021

机译：抗BCMA汽车T细胞疗法在复发/难治多骨髓瘤和血浆细胞白血病中研究抗BCMA汽车T细胞疗法研究

Overview of anti‐BCMA CAR‐T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma

著录项

引文网络

相似文献

相关主题

期刊订阅